Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS1001): an international, open-label, randomised, controlled, phase 3, multicentre trial - Gronchi, A; Ferrari, S; Quagliuolo, V (Lancet Oncol, 2017)